Christopher T Ritchlin (Christopher Ritchlin, C T Ritchlin, Christopher T Richlin)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 70

Top Venues

Clinical rheumatology

Arthritis & rheumatology (Hoboken, N.J.)

RMD open

The Journal of rheumatology. Supplement

University of Rochester Medical Center

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Rochester Medical Center Jul 01 1998

United States

Professor/ Division Chief :: Allergy, Immunology & Rheumatology

Publications

Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology (2024)
Oliver M FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) 76 (9) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Oliver M FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Phillip J Mease, Joseph Frank Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Christopher T Ritchlin, Robert B M Landewe, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C Coates
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatology and therapy (2024)
Oliver FitzGerald, Dafna D Gladman, Phillip J Mease, Christopher T Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, Ian Catlett
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Daniela Kampel Stolnicki, Laura C Coates, Charlotte E Gollins, Sahil Koppikar, Lourdes Maria Perez-Chada, Lluis L Puig, Philip S Helliwell, Atul A Deodhar, Christopher T Ritchlin, Samuel T Hwang, Cláudia Goldenstein-Schainberg
Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease. The Journal of rheumatology (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Vinod Chandran, Dafna D Gladman, Phillip J Mease, Lihi Eder, Stephen R Pennington, Oliver M FitzGerald, Christopher T Ritchlin, Dan E Webster, Kurt de Vlam, Wilson Liao
GRAPPA 2023 Collaborative Research Network Meeting. The Journal of rheumatology (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Laura C Coates, Robert B M Landewe, Iain B McInnes, Phillip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD open 10 (1) (2024)
Proton Rahman, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, Phillip J Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, Dennis G McGonagle
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical rheumatology 43 (5) (2024)
Ying Ying Leung, Arthur Kavanaugh, Christopher T Ritchlin
Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Anti-TNF inhibitor. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Dennis McGonagle, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, May Shawi, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Stephen Xu, Christopher T Ritchlin, Proton Rahman, Phillip J Mease
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR open rheumatology (2023)
Christopher T Ritchlin, Atul A Deodhar, Wolf-Henning Boehncke, Enrique Roberto Soriano, Alexa P Kollmeier, Xie L Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S Helliwell
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. ACR open rheumatology 5 (3) (2023)
Christopher T Ritchlin, Laura C Coates, Philip J Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P Kollmeier, Proton Rahman
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. Trials 24 (1) (2023)
Christopher T Ritchlin, Atul A Deodhar, Wolf-Henning Boehncke, Enrique Roberto Soriano, Alexa P Kollmeier, Xie L Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S Helliwell
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. ACR open rheumatology (2023)
Christopher T Ritchlin, Atul A Deodhar, Wolf-Henning Boehncke, Enrique Roberto Soriano, Alexa P Kollmeier, Xie L Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S Helliwell
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. ACR open rheumatology 5 (3) (2023)
Christopher T Ritchlin, Atul A Deodhar, Wolf-Henning Boehncke, Enrique Roberto Soriano, Alexa P Kollmeier, Xie L Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S Helliwell
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. ACR open rheumatology 5 (3) (2023)
Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Phillip J Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B M Landewe
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Annals of the rheumatic diseases (2023)
Christopher T Ritchlin, Laura C Coates, Philip J Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P Kollmeier, Proton Rahman
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. Trials 24 (1) (2023)
Stefan Siebert, Kristen M Sweet, Christopher T Ritchlin, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron
Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials. ACR open rheumatology (2023)
Rochelle L Castillo, Ikjot Sidhu, Igor Dolgalev, Tinyi Chu, Aleksandr Prystupa, Ipsita Subudhi, Di Yan, Piotr Konieczny, Brandon Hsieh, Rebecca H Haberman, Shanmugapriya Selvaraj, Tomoe Shiomi, Rhina Medina, Parvathy Vasudevanpillai Girija, Adriana Heguy, Cynthia A Loomis, Luis A Chiriboga, Christopher T Ritchlin, Maria De La Luz Garcia-Hernandez, John A Carucci, Shane A Meehan, Andrea L Neimann, Johann E Gudjonsson, Jose U Scher, Shruti Naik
Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems. Science immunology 8 (84) (2023)
Christopher T Ritchlin, Laura C Coates, Philip J Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P Kollmeier, Proton Rahman
The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. Trials 24 (1) (2023)
Lihi Eder, Ker-Ai Lee, Vinod Chandran, Jessica Widdifield, Aaron M Drucker, Christopher T Ritchlin, Cheryl F Rosen, Richard J Cook, Dafna D Gladman
Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention. Arthritis & rheumatology (Hoboken, N.J.) (2023)
Carmel Stober, Iain B McInnes, Soumya Raychaudhuri, Phillip J Mease, Stephen R Pennington, Jose U Scher, Vinod Chandran, April W Armstrong, Maarten P T de Wit, Alberto Cauli, Deepak R Jadon, Thorvardur Jon Love, Philip S Helliwell, Denis O'Sullivan, Leonieke J J van Mens, Christopher T Ritchlin, Oliver M FitzGerald
Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting. The Journal of rheumatology 49 (6 Suppl 1) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Laura C Coates, Iain B McInnes, Joseph F Merola, Richard B Warren, Arthur Kavanaugh, Alice B Gottlieb, Laure Gossec, Deepak Assudani, Rajan Bajracharya, Jason Coarse, Barbara Ink, Christopher T Ritchlin
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. Arthritis & rheumatology (Hoboken, N.J.) (2022)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F Merola, Iain B McInnes, Atul Deodhar
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD open 8 (1) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Javier Rangel-Moreno, Maria De La Luz Garcia-Hernandez, Teresa Owen, Jennifer Barnard, Enrique Becerril-Villanueva, Trinayan Kashyap, Christian Argueta, Armando Gamboa-Dominguez, Sharon Tamir, Yosef Landesman, Bruce I Goldman, Christopher T Ritchlin, Jennifer H Anolik
Small Molecule Inhibitors of Nuclear Export and the Amelioration of Lupus by Modulation of Plasma Cell Generation and Survival. Arthritis & rheumatology (Hoboken, N.J.) 74 (8) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Ananta Paine, Paul S Brookes, Soumyaroop Bhattacharya, Dongmei Li, Maria De La Luz Garcia-Hernandez, Francisco Tausk, Christopher T Ritchlin
Dysregulation of Bile Acids, Lipids, and Nucleotides in Psoriatic Arthritis Revealed by Unbiased Profiling of Serum Metabolites. Arthritis & rheumatology (Hoboken, N.J.) (2022)
Effie Pournara, Matthias Kormaksson, Peter Nash, Christopher T Ritchlin, Bruce W Kirkham, Gregory Ligozio, Luminita Pricop, Alexis Ogdie, Laura C Coates, Georg Schett, Iain B McInnes
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD open 7 (3) (2022)
Philip S Helliwell, Christopher T Ritchlin
Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting. The Journal of rheumatology (2021)
Christopher T Ritchlin, April W Armstrong, Hanna J Johnsson, Michelle L M Mulder
GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations. The Journal of rheumatology (2021)
Christopher T Ritchlin, Stephen R Pennington, Nick J Reynolds, Oliver M FitzGerald
Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. The Journal of rheumatology. Supplement 96 (2021)
Jose U Scher, Alexis Ogdie, Joseph F Merola, Christopher T Ritchlin
Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 73 (9) (2021)
Catherine D Hughes, Leonieke J J van Mens, Wolf-Henning Boehncke, Christopher T Ritchlin
GRAPPA Trainees Symposium 2019: A Report from the GRAPPA 2019 Annual Meeting. The Journal of rheumatology. Supplement 96 (2021)
Robin Waxman, Carmel Stober, Deepak R Jadon, Ana Maria Orbai, Vinod Chandran, Philip S Helliwell, Stephen R Pennington, Maarten de Wit, Denis O'Sullivan, Phillip J Mease, April W Armstrong, Kristina Callis Duffin, Philip S Helliwell, Leonieke J J van Mens, Christopher T Ritchlin, Oliver M FitzGerald
Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting. The Journal of rheumatology. Supplement 96 (2021)
Jon T Giles, Alexis Ogdie, Juan J Gomez Reino, Philip S Helliwell, Rebecca Germino, Lori Stockert, Pamela Young, Wael Joseph, Rajiv Mundayat, Daniela Graham, Christopher T Ritchlin
Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD open 7 (1) (2021)
Carmel Stober, Deepak R Jadon, April W Armstrong, Vinod Chandran, Maarten de Wit, Philip S Helliwell, Phillip J Mease, Philip S Helliwell, Denis O'Sullivan, Stephen R Pennington, Thorvardur Jon Love, Alberto Cauli, Leonieke J J van Mens, Robin Waxman, Jose U Scher, Richard B Warren, Christopher T Ritchlin, Oliver M FitzGerald
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting. The Journal of rheumatology (2021)
Philip S Helliwell, Christopher T Ritchlin
Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting. The Journal of rheumatology. Supplement 97 (2021)
Niti Goel, Laura C Coates, Gabriele de Marco, Lihi Eder, Oliver M FitzGerald, Philip S Helliwell, Ying Ying Leung, Walter P Maksymowych, Phillip J Mease, Mikkel Østergaard, Denis O'Sullivan, Denis Poddubnyy, Christopher T Ritchlin, Dafna D Gladman
GRAPPA 2019 Project Report. The Journal of rheumatology. Supplement 96 (2021)
Richard D Bell, Homaira Rahimi, H Mark Kenney, Alicia A Lieberman, Ronald W Wood, Edward M Schwarz, Christopher T Ritchlin
Altered Lymphatic Vessel Anatomy and Markedly Diminished Lymph Clearance in Affected Hands of Patients With Active Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 72 (9) (2021)
Christopher T Ritchlin, April W Armstrong, Hanna J Johnsson, Michelle L M Mulder
GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations. The Journal of rheumatology. Supplement 97 (2021)
Christopher T Ritchlin
Navigating the diverse immune landscapes of psoriatic arthritis. Seminars in immunopathology 43 (2) (2021)
Elana Meer, Joseph F Merola, Robert Fitzsimmons, Thorvardur Jon Love, Shiyu Wang, Daniel Shin, Yong Chen, Sharon Xie, Hyon Choi, Yuqing Zhang, Jose U Scher, Christopher T Ritchlin, Joel M Gelfand, Philip S Helliwell
Does biologic therapy impact the development of PsA among patients with psoriasis? Annals of the rheumatic diseases (2021)
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Enrique Roberto Soriano, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Shihong Sheng, Yusang Jiang, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, May Shawi, Chetan S Karyekar, Atul Deodhar
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. RMD open 7 (1) (2021)
Carmel Stober, Deepak R Jadon, April W Armstrong, Vinod Chandran, Maarten de Wit, Philip S Helliwell, Phillip J Mease, Philip S Helliwell, Denis O'Sullivan, Stephen R Pennington, Thorvardur Jon Love, Alberto Cauli, Leonieke J J van Mens, Robin Waxman, Jose U Scher, Richard B Warren, Christopher T Ritchlin, Oliver M FitzGerald
Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting. The Journal of rheumatology. Supplement 97 (2021)
Christopher T Ritchlin
In Memoriam: Evan Calkins, MD, 1920-2020. Arthritis & rheumatology (Hoboken, N.J.) 72 (8) (2020)
Allen Anandarajah, Caroline Thirukumaran, Katherine McCarthy, Sean McMahon, Changyong Feng, Christopher T Ritchlin
Identification and Characterization of a High-Need, High-Cost group among Hospitalized SLE patients. Arthritis care & research (2020)
Christopher T Ritchlin, Jon T Giles, Philip S Helliwell, Juan J Gomez-Reino, Philip S Helliwell, Pamela Young, Cunshan Wang, Joseph Wu, Ana Belén Romero, John Woolcott, Lori Stockert
Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR open rheumatology 2 (10) (2020)
Richard D Bell, R James White, Maria L Garcia-Hernandez, Emily Wu, Homaira Rahimi, Roberta G Marangoni, Pamelia Slattery, Stacey Duemmel, Marc Nuzzo, Nelson Huertas, Min Yee, Michael A O'Reilly, Craig Morrell, Christopher T Ritchlin, Edward M Schwarz, Benjamin D Korman
Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis & rheumatology (Hoboken, N.J.) 72 (10) (2020)
Emily K Wu, Zoe I Henkes, Brion McGowan, Richard D Bell, Moises J Velez, Alexandra M Livingstone, Christopher T Ritchlin, Edward M Schwarz, Homaira Rahimi
TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21+/CD23- B Cell Follicles Is Prevented with Anti-TNF Therapy. Journal of immunology (Baltimore, Md. : 1950) 203 (11) (2019)
Niti Goel, Oliver M FitzGerald, Dafna D Gladman, Philip S Helliwell, Arthur Kavanaugh, Walter P Maksymowych, Phillip J Mease, Christopher T Ritchlin, Laura C Coates
GRAPPA 2018 Project Report. The Journal of rheumatology. Supplement 95 (2019)

Christopher T Ritchlin.css-eqlu8i{font-size:small;padding-left:4px;} (Christopher Ritchlin, C T Ritchlin, Christopher T Richlin)

Publication Activity (10 Years)

Top Topics

Top Venues

Christopher T Ritchlin (Christopher Ritchlin, C T Ritchlin, Christopher T Richlin)